MoMoGains| Next 10 |
DCPH News and Press, Deciphera Pharmaceuticals Inc.
-
- Ripretinib Marketing Applications Submitted to Health Canada and Australia’s Therapeutic Goods Administration for Patients with Advanced GIST via the U.S. FDA’s Project Orbis Pilot Program - - Commercial Preparations Underway to Support Potential Approval and Launch of ...
-
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
-
Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...
-
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company addressing key mechanisms of tumor drug resistance, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 38 th Annual J.P. Morgan Healthcare Conference on Monda...
-
Shares of Deciphera Pharmaceuticals (NASDAQ: DCPH) lept over 31% last month, according to data from S&P Global Market Intelligence . The monthly run-up topped 45% at one point before shares cooled off in the final days of the decade. Despite that, the stock erupted for a 196% gain ...
-
The FDA Breakthrough Therapy Designation (BTD) was an offshoot of the Food and Drug Administration Safety and Innovation Act (FDASIA) that was signed on July 9, 2012 , that called for a new designation to be created. Since 2012, only 147 drugs have been approved having this designation, which...
-
- Application is Being Reviewed Under FDA's Real-Time Oncology Review (RTOR) Pilot Program - - Positive Results from Company’s INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) Form Basis of Submission - D...
-
Biotech investors are on the edge of their seats this holiday season thanks to a recent string of juicy buyout offers. Despite a busy year for acquisitions, big pharmaceutical companies with pipelines to fill and money to spend have been jumping over each other to acquire smaller biotechs at ste...
-
The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with this Read more ...
-
Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK). More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Health...
Stock Information
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
MENU
DCPH
DCPH Quote
DCPH Short
DCPH News
DCPH Articles
DCPH Message Board
Get DCPH Alerts
News, Short Squeeze, Breakout and More Instantly...
RECENT DCPH NEWS
-
- Ripretinib Marketing Applications Submitted to Health Canada and Australia’s Therapeutic Goods Administration for Patients with Advanced GIST via the U.S. FDA’s Project Orbis Pilot Program - - Commercial Preparations Underway to Support Potential Approval and Launch of ...
-
Biotech Pulse The biotech group closed 2019 with its longest rally of the year. It was a welcome change from what had mostly been an uphill battle. While the broader market was sailing from one high to another, biotechs and pharmaceuticals (biopharma) were still marking their 2019 lows in ea...
-
Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...
